Immunovo BV, a ‘s-Hertogenbosch, The Netherlands-based new biotechnology company looking to combine novel methods in immunotherapy with the most recent insights in oncology to develop novel therapeutics, secured seed funding from Dutch venture capital firms. The investment was made by Biox Biosciences BV and LUPUS Ventures BV.
In conjunction with the funding, founding investors Jan van der Hoeven, Biox Biosciences and Cees de Wolff, Lupus Ventures, will join the company’s board of directors.
Immunovo is a spin-out from Pepscan Therapeutics in Lelystad. Its technology platform is based on the pioneering work of Pepscan’s founding scientist Professor Rob Meloen.
The new company is managed by Dr. Joost van Bree (Chief Executive Officer) and Dr. Evert Jan Schenkelaars (Chief Medical Officer).
Commenting on the company’s targets, Joost van Bree, was quoted to say: “Immunovo aims to develop its proprietary technology to create a pipeline of immunotherapeutic drugs which have the potential to be truly potent and effective medicines”.
FinSMEs
28/04/2010